X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FRESENIUS KABI ONCO. ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x - 22.1 - View Chart
P/BV x 7.6 3.1 243.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
FRESENIUS KABI ONCO.
Mar-13
ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,589176 902.8%   
Low Rs1,23279 1,569.4%   
Sales per share (Unadj.) Rs417.537.7 1,107.7%  
Earnings per share (Unadj.) Rs56.35.1 1,105.3%  
Cash flow per share (Unadj.) Rs64.76.7 962.5%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.942.5 688.5%  
Shares outstanding (eoy) m119.57158.23 75.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 100.1%   
Avg P/E ratio x25.125.0 100.3%  
P/CF ratio (eoy) x21.818.9 115.2%  
Price / Book Value ratio x4.83.0 161.0%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65320,135 837.6%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m9,171703 1,304.2%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m49,9155,963 837.1%  
Other income Rs m1,64518 9,139.4%   
Total revenues Rs m51,5615,981 862.1%   
Gross profit Rs m8,4821,430 593.1%  
Depreciation Rs m1,006258 390.0%   
Interest Rs m671-26 -2,579.2%   
Profit before tax Rs m8,4511,216 694.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,606342 469.3%   
Profit after tax Rs m6,731806 835.2%  
Gross profit margin %17.024.0 70.9%  
Effective tax rate %19.028.1 67.5%   
Net profit margin %13.513.5 99.8%  
BALANCE SHEET DATA
Current assets Rs m27,0625,102 530.5%   
Current liabilities Rs m15,3242,385 642.4%   
Net working cap to sales %23.545.6 51.6%  
Current ratio x1.82.1 82.6%  
Inventory Days Days67150 44.3%  
Debtors Days Days41113 36.4%  
Net fixed assets Rs m12,6105,148 244.9%   
Share capital Rs m239158 151.1%   
"Free" reserves Rs m34,4906,556 526.1%   
Net worth Rs m35,0276,732 520.3%   
Long term debt Rs m1,212952 127.2%   
Total assets Rs m54,38710,388 523.6%  
Interest coverage x13.6-45.8 -29.7%   
Debt to equity ratio x00.1 24.5%  
Sales to assets ratio x0.90.6 159.9%   
Return on assets %13.67.5 181.3%  
Return on equity %19.212.0 160.5%  
Return on capital %24.914.6 170.2%  
Exports to sales %12.974.5 17.4%   
Imports to sales %3.124.8 12.5%   
Exports (fob) Rs m6,4614,441 145.5%   
Imports (cif) Rs m1,5401,477 104.3%   
Fx inflow Rs m6,5635,298 123.9%   
Fx outflow Rs m3,0121,772 169.9%   
Net fx Rs m3,5523,525 100.7%   
CASH FLOW
From Operations Rs m7,2591,274 569.7%  
From Investments Rs m1,864-1,204 -154.8%  
From Financial Activity Rs m-9,273-196 4,728.6%  
Net Cashflow Rs m-150-126 118.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 9.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 42,599 160.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS